(Q50139842)

25 February 2018

title

The cost of hepatitis A infections in American adolescents and adults in 1997. (English)

1 reference

25 February 2018

1 reference

1 reference

Berge JJ

1

1 reference

25 February 2018

Drennan DP

2

1 reference

25 February 2018

Jacobs RJ

3

1 reference

25 February 2018

Jakins A

4

1 reference

25 February 2018

Meyerhoff AS

5

1 reference

25 February 2018

Stubblefield W

6

1 reference

25 February 2018

Weinberg M

7

1 reference

25 February 2018

language of work or name

English

0 references

publication date

1 February 2000

1 reference

25 February 2018

published in

Hepatology

1 reference

25 February 2018

volume

31

1 reference

25 February 2018

issue

2

1 reference

25 February 2018

page(s)

469-473

1 reference

25 February 2018

Qualitative Research: Consensus methods for medical and health services research

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

Early indicators of prognosis in fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

Will hepatitis A become a vaccine-preventable disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Cost-effectiveness analysis of hepatitis A prevention in travellers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Cost-effectiveness analysis of vaccination against hepatitis A in travellers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

The effect of underreporting on the apparent incidence and epidemiology of acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Etiology of fulminant viral hepatitis in Greece

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.510310229

1 reference

7 January 2021

The measurement of indirect costs in the health economics evaluation literature. A review

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

The cost of a food-borne outbreak of hepatitis A in Denver, Colo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

British psychiatric morbidity survey

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

The direct medical costs of osteoporosis for American women aged 45 and older, 1986.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310229

7 January 2021

Identifiers

DOI

10.1002/HEP.510310229

1 reference

25 February 2018

1 reference

25 February 2018